DE202015002279U1 - Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels - Google Patents
Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels Download PDFInfo
- Publication number
- DE202015002279U1 DE202015002279U1 DE202015002279.0U DE202015002279U DE202015002279U1 DE 202015002279 U1 DE202015002279 U1 DE 202015002279U1 DE 202015002279 U DE202015002279 U DE 202015002279U DE 202015002279 U1 DE202015002279 U1 DE 202015002279U1
- Authority
- DE
- Germany
- Prior art keywords
- extract
- dietary supplement
- chromium
- another
- cas number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 11
- 210000004369 blood Anatomy 0.000 title description 4
- 239000008280 blood Substances 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 11
- 241000051611 Salacia oblonga Species 0.000 claims abstract description 7
- OMKXVFDVAGCPBS-GTEYUELZSA-N [(2s,3s,4r,5r,6s)-1-[(2r,3s,4s)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](OS([O-])(=O)=O)[C@H](O)C[S+]1C[C@@H](O)[C@H](O)[C@H]1CO OMKXVFDVAGCPBS-GTEYUELZSA-N 0.000 claims abstract description 7
- SOWRVDSZMRPKRG-YRPOCYRVSA-N S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] Chemical compound S(=O)(=O)(O[C@@H](CO)[C@@H](C[S@+]1[C@@H]([C@H]([C@@H](C1)O)O)CO)O)[O-] SOWRVDSZMRPKRG-YRPOCYRVSA-N 0.000 claims abstract description 3
- 239000000419 plant extract Substances 0.000 claims abstract 4
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 claims description 6
- 244000302512 Momordica charantia Species 0.000 claims description 5
- 235000009811 Momordica charantia Nutrition 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- 101710163504 Phaseolin Proteins 0.000 claims description 3
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 229940064958 chromium citrate Drugs 0.000 claims 1
- 150000001845 chromium compounds Chemical class 0.000 claims 1
- 229940046374 chromium picolinate Drugs 0.000 claims 1
- 229940060736 chromium polynicotinate Drugs 0.000 claims 1
- SWXXYWDHQDTFSU-UHFFFAOYSA-K chromium(3+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cr+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SWXXYWDHQDTFSU-UHFFFAOYSA-K 0.000 claims 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000011746 zinc citrate Substances 0.000 claims 1
- 235000006076 zinc citrate Nutrition 0.000 claims 1
- 229940068475 zinc citrate Drugs 0.000 claims 1
- 150000003752 zinc compounds Chemical class 0.000 claims 1
- 239000011670 zinc gluconate Substances 0.000 claims 1
- 235000011478 zinc gluconate Nutrition 0.000 claims 1
- 229960000306 zinc gluconate Drugs 0.000 claims 1
- 239000011787 zinc oxide Substances 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 101710190529 Insulin-like peptide Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 239000003392 amylase inhibitor Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100033407 Alpha-amylase 2B Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000732641 Homo sapiens Alpha-amylase 2B Proteins 0.000 description 1
- 101000693011 Homo sapiens Pancreatic alpha-amylase Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 1
- 241000647991 Salacia reticulata Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- MNTPVGSKXQLHFZ-UHFFFAOYSA-N [SH3+].[SH3+].[O-]S([O-])(=O)=O Chemical group [SH3+].[SH3+].[O-]S([O-])(=O)=O MNTPVGSKXQLHFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass eine beliebige Konzentration eines Extraktes von Salacia oblonga oder eines anderen Salacinol (CAS-Nummer: 200399-47-9) und Kotalanol (CAS-Nummer: 214491-07-3) beinhaltenden Pflanzenextraktes enthalten ist.
Description
- Die vorliegende Erfindung bezeichnet ein Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels.
- Die Glucose-Konzentration im Blut wird durch einen hormonellen Regelkreis gesteuert. Dafür verantwortlich sind die Hormone Insulin und Glucagon. Während die Glucagonausschüttung bei einer Hypoglykämie zur Erhöhung des Blutglucosewertes führt, wird dieser durch eine Insulinfreisetzung bei einer Hyperglykämie gesenkt. Dabei katalysiert Insulin den Übertritt der Glucose aus dem Blutplasma und der Interstitialflüssigkeit durch die Zellwand in die Zelle. Vorwiegend in Hepatozyten und Myozyten, wird Glucose dann in Form von Glykogen gespeichert. In Abhängigkeit von genetischer Disposition oder verschiedenen Pathogenitätsfaktoren, wie zum Beispiel eine unzureichende Menge oder fehlerhafte Beschaffenheit des Insulins beziehungsweise relevanter Rezeptoren oder einer in den Industrienationen weit verbreiteten Fehlernährung, ist dieser Prozess mehr oder minder effektiv. Um einem derartigen Missverhältnis entgegenzuwirken, ist eine gezielte Nahrungsergänzung aus ernährungsphysiologischer Sicht als sinnvoll zu beurteilen.
- Das vorliegende Kombinationspräparat beinhaltet eine Zusammensetzung pflanzlicher Extrakte, deren Inhaltsstoffe als Multi-Target-Drug einer Hyperglykämie entgegenwirken. Ein 4-Komponentensystem umfasst dabei die Applikation insulinähnlicher Peptide, Alpha-Amylase-Inhibition, Alpha-Glucosidase-Inhibition und eine Minearalstoffsupplementierung. Zu diesem Zweck enthält das Präparat die Extrakte von Salacia oblonga, Momordica charantia, Phaseolus vulgaris sowie Zink und Chrom in bioverfügbarer Form.
- 1. Alpha-Glycosidase-Inhibition mit Salacia oblonga Extrakt
- Salacia oblonga enthält die Alpha-Glycosidase-Inhibitoren Kotalanol [1] und Salacinol [2]. Durch die Inhibition der mukosalen Alpha-Glycosidase wird bei einer Gabe von 240 mg Salacia oblonga Extrakt eine um 14% reduzierte Glucoseaufnahme, bei einer Gabe von 480 mg Salacia oblonga Extrakt eine um 22% reduzierte Glucoseaufnahme erzielt [3].
- 2. Alpha-Amylase-Inhibition mit Phaseolus vulgaris Extrakt
- Das Enzym Alpha-Amylase spaltet die Alpha-1,4-Glykosidbindung der Amylose. Dadurch entstehen Dextrine und daraus Maltose, Glucose sowie verzweigte Oligosaccharide. Das Glycoprotein-Gemisch Phaseolin ist das Hauptreserveprotein von Phaseolus vulgaris und hat einen Anteil von 30–50% an den Samenproteinen. Phaseolin inhibiert die Pankreasamylase Isoformen AMY2A und AMY2B und verringert somit den Anteil an verwertbaren Kohlenhydraten in der zugeführten Nahrung signifikant. Davon betroffen sind vor allem Nahrungsmittel mit hohem Amylosegehalt, wie zum Beispiel Nudeln, Kartoffeln, Reis, Brot und andere Backwaren [4].
- 3. Applikation insulinähnlicher Peptide durch Momordica charantia Extrakt
- Momordica charantia enthält große Mengen Polypeptid-P. Dabei handelt es sich um ein insulinähnliches, hypoglykämisches Protein, dass die Insulinwirkung im Körper imitiert. Im Gegensatz zu Insulin, das bei oraler Applikation eine unzureichende Bioverfügbarkeit aufweist, zeigt der Samenextrakt von Momordica charantia bei oraler Applikation eine signifikante hypoglykämische Wirkung [5].
- 4. Mineralstoffsupplementierung mit Zink und Chrom
- Um einem Mineralstoffmangel, den Glucosestoffwechsel betreffend, vorzubeugen, sind dem Präparat Chrom und Zink in einer bioverfügbaren Form zugesetzt. Eine Supplementierung mit Chrom [6] und Zink [7] ist bei gestörtem Glucosestoffwechsel als sinnvoll zu beurteilen.
- Referenzen
-
- [1] YOSHIKAWA, M.; MURAKAMI, T.; YASHIRO, K et al.: Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata. Chem Pharm Bull (Tokyo). 1998 Aug; 46(8): 1339–40
- [2] YOSHIKAWA, M.; MORIKAWA, T.; MATSUDA, H. et al.: Absolute Stereostructure of Potent alpha-Glucosidase Inhibitor, Salacinol, with Unique Thiosugar Sulfonium Sulfate Inner Salt Structure from Salacia reticulata. Bioorg Med Chem 2002 May; 10(5): 1547–54
- [3] WILLIAMS, JA; CHOE YS; NOSS MJ; BAUMGARTNER CJ; MUSTAD VA: Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes, Am J Clin Nutr. 2007 Jul; 86(1): 124–30.
- [4] SCHMITT, P.: Nutritional supplement contributing a calorie-reduced nutrition, German patent 2014 Jun;
DE 20 2014 003 391 U1 - [5] BABY JOSEPH; D. JINI: Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency, Asian Pac J Trop Dis. 2013 Apr; 3(2): 93–102. doi: 10.1016/S2222-1808(13)60052-3
- [6] BALK, E. M.; TATSIONI, A.; LICHTENSTEIN, A. H.; LAU, J.; PITTAS, A. G.: Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30(8): 2154–2163.
- [7] JAYAWARDENA, R.; RANASINGHE, P.; GALAPPATTHY, P.; et. al.: Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis, Diabetol Metab Syndr. 2012; 4: 13. Published online 2012 Apr 19. doi: 10.1186/1758-5996-4-13
Claims (7)
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass eine beliebige Konzentration eines Extraktes von Salacia oblonga oder eines anderen Salacinol (CAS-Nummer: 200399-47-9) und Kotalanol (CAS-Nummer: 214491-07-3) beinhaltenden Pflanzenextraktes enthalten ist.
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass eine beliebige Konzentration eines Extraktes von Phaseolus vulgaris oder eines anderen Phaseolin (UniProt-Nummer: P07219) beinhaltenden Pflanzenextraktes enthalten ist.
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass eine beliebige Konzentration eines Extraktes von Momordica charantia oder eines anderen Poplypeptid-P (UniProt-Nummer: E2JCD2) beinhaltenden Pflanzenextraktes enthalten ist.
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass Zinkcitrat (CAS-Nummer: 546-46-3) beziehungsweise eine andere organische oder anorganische Zinkverbindung wie beispielsweise Zinkgluconat oder Zinkoxid enthalten ist.
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass Chrompicolinat (CAS-Nummer: 14639-25-9) beziehungsweise eine andere organische oder anorganische Chromverbindung wie beispielsweise Chrom-Polynicotinat oder Chromcitrat enthalten ist.
- Nahrungsergänzungsmittel dadurch gekennzeichnet, dass die Applikationsform als Tablette oder Pulver oder Filmtablette oder Dragee oder Weichgelatinekapsel oder Hartgelatinekapsel oder Oblong oder Caplet oder Pille oder Granulat vorliegt.
- Nahrungsergänzungsmittel, dadurch gekennzeichnet, dass eine Kombination von mindestens zwei der Merkmale [1] bis [3], mit [4] oder [5] und [6] vorliegt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE202015002279.0U DE202015002279U1 (de) | 2015-03-24 | 2015-03-24 | Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE202015002279.0U DE202015002279U1 (de) | 2015-03-24 | 2015-03-24 | Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE202015002279U1 true DE202015002279U1 (de) | 2015-05-06 |
Family
ID=53185706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE202015002279.0U Expired - Lifetime DE202015002279U1 (de) | 2015-03-24 | 2015-03-24 | Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE202015002279U1 (de) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202014003391U1 (de) | 2014-04-22 | 2014-06-05 | Patrick Schmitt | Nahrungsergänzungsmittel zur Unterstützung einer kalorienreduzierten Ernährung |
-
2015
- 2015-03-24 DE DE202015002279.0U patent/DE202015002279U1/de not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202014003391U1 (de) | 2014-04-22 | 2014-06-05 | Patrick Schmitt | Nahrungsergänzungsmittel zur Unterstützung einer kalorienreduzierten Ernährung |
Non-Patent Citations (6)
| Title |
|---|
| BABY JOSEPH; D. JINI: Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency, Asian Pac J Trop Dis. 2013 Apr; 3(2): 93-102. doi: 10.1016/S2222-1808(13)60052-3 |
| BALK, E. M.; TATSIONI, A.; LICHTENSTEIN, A. H.; LAU, J.; PITTAS, A. G.: Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care 2007; 30(8): 2154-2163 |
| JAYAWARDENA, R.; RANASINGHE, P.; GALAPPATTHY, P.; et. al.: Effects of zinc supplementation on diabetes mellitus: a systematic review and meta-analysis, Diabetol Metab Syndr. 2012; 4: 13. Published online 2012 Apr 19. doi: 10.1186/1758-5996-4-13 |
| WILLIAMS, JA; CHOE YS; NOSS MJ; BAUMGARTNER CJ; MUSTAD VA: Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes, Am J Clin Nutr. 2007 Jul; 86(1): 124-30 |
| YOSHIKAWA, M.; MORIKAWA, T.; MATSUDA, H. et al.: Absolute Stereostructure of Potent alpha-Glucosidase Inhibitor, Salacinol, with Unique Thiosugar Sulfonium Sulfate Inner Salt Structure from Salacia reticulata. Bioorg Med Chem 2002 May; 10(5): 1547-54 |
| YOSHIKAWA, M.; MURAKAMI, T.; YASHIRO, K et al.: Kotalanol, a potent alpha-glucosidase inhibitor with thiosugar sulfonium sulfate structure, from antidiabetic ayurvedic medicine Salacia reticulata. Chem Pharm Bull (Tokyo). 1998 Aug; 46(8): 1339-40 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Waheed et al. | Honey and cancer: A mechanistic review | |
| Vincent | New evidence against chromium as an essential trace element | |
| Samad et al. | Therapeutic effects of vinegar: A review | |
| Zhang et al. | Effect of tea products on the in vitro enzymatic digestibility of starch | |
| Smith | Therapeutic applications of fenugreek | |
| TW425285B (en) | Fish oil and garlic nutritive supplement | |
| US20070202215A1 (en) | Dietary nutritional supplements for persons consuming alcohol products | |
| WO2014127000A2 (en) | Methods and diets to protect against chemotoxicity and age related illnesses | |
| Duraiswamy et al. | Development of an antidiabetic formulation (ADJ6) and its inhibitory activity against α-amylase and α-glucosidase | |
| Afolayan et al. | Dietary supplements in the management of hypertension and diabetes-a review | |
| CN102048002B (zh) | 一种石斛茶饮料 | |
| CN104758920A (zh) | 一种基于药食同源的痛风保健品 | |
| Ulbricht et al. | An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the natural standard research collaboration | |
| WO2020039277A1 (en) | Enteral or oral nutritional composition | |
| Dinesh et al. | Therapeutic applications of plant and nutraceutical-based compounds for the management of type 2 diabetes mellitus: a narrative review | |
| Hassani et al. | The effect of combined therapy with fenugreek and nutrition training based on Iranian traditional medicine on FBS, HgA1c, BMI, and waist circumference in Type 2 diabetic patients: a randomized double blinded clinical trial | |
| DE202015002279U1 (de) | Nahrungsergänzungsmittel zur Aufrechterhaltung eines normalen Blutzuckerspiegels | |
| Bikash et al. | Formulating anti-diabetic nutraceutical tablets based on edible plants from Tripura, India | |
| Navaro et al. | Functional foods in fad diets: A review | |
| Mir et al. | Antidiabetic properties and metal analysis of Bombax ceiba flower extracts | |
| Mozersky | Herbal products and supplemental nutrients used in the management of diabetes | |
| AU2022202545A1 (en) | Oral hypoglycemic agents as food additives and supplements | |
| Jing et al. | Antioxidative and hypoglycemic effect of ta-ermi extracts on streptozotocin-induced diabetes | |
| Kumar et al. | Sugar and Chronic diseases | |
| Nair et al. | A review on the role of functional foods and derivatives for diabetes management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 20150611 |
|
| R081 | Change of applicant/patentee |
Owner name: BAKHROM, BISHAN, DE Free format text: FORMER OWNER: SCHMITT, PATRICK, 55122 MAINZ, DE Effective date: 20150519 |
|
| R156 | Lapse of ip right after 3 years | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A23L0001290000 Ipc: A23L0033105000 |